A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-vs.-host disease (GVHD) and non-relapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T-replete HLA-mismatched HSCT, and may also benefit myelo...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Biol Blood Marrow Transplant
Κύριοι συγγραφείς: Koreth, John, Kim, Haesook T., Lange, Paulina B., Bindra, Bhavjot, Reynolds, Carol G., Chammas, Marie J., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Glotzbecker, Brett, Nikiforow, Sarah, Ritz, Jerome, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Alyea, Edwin P.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2015
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604028/
https://ncbi.nlm.nih.gov/pubmed/26055298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.05.027
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια